The Importance of an Opioid Emergency Plan Includes Amplifying the Voice for Take-Home Naloxone

Sponsored by kaléo

This activity is not certified for credit.

Date
Thursday, September 8

Start Time
3:40p

End Time
4:30p

Room
Castellana Ballroom
Level 3

Program Description
Opioid related deaths, from both heroin and prescription opioids, have reached epidemic levels in the United States, with more people dying in 2014 than during any previous year on record. A large proportion of opioid emergencies in patients prescribed opioids for pain, resulting in life-threatening opioid induced respiratory depression (OIRD), are unintentional. Seconds count with life-threatening OIRD, and without intervention hypoxia may result in brain injury and death in as little as 4 minutes. However, the average emergency medical services (EMS) response time is approximately 9.4 minutes. Most opioid emergencies occur in the home and are witnessed by friends or family members who may be in the best position to intervene quickly prior to EMS arrival. Injectable naloxone has been FDA-approved for more than 40 years, used primarily in the hospital setting or by EMS to reverse OIRD. Many state, national, and international government and professional organizations are calling for naloxone to be readily accessible to individuals likely to witness a life-threatening opioid emergency.

During this program, the faculty will present the epidemiology of opioid emergencies, provide guidance on how to identify and communicate with at-risk pain patients, and offer strategies to help patients develop an opioid emergency plan.

Learning Objectives
After attending this PDM program, participants should be better able to:

  • Cite evidence for the growth in opioid emergencies and the resulting public health epidemic
  • Identify and communicate with patients at increased risk for an opioid emergency
  • Understand their role in helping patients develop an opioid emergency plan

Faculty

Eric S. Edwards, MD, PhD
Jeffrey A. Gudin, MD
Sanford M. Silverman, MD

Registration Website
https://www.surveymonkey.com/r/kaleoPDM2016

Contact Name
Samantha Libby-Cap

Contact Phone
(860) 575-5360

Contact email
slibbycap@pharmacomgroup.com

Related Content